M. Seppänen, I. Laaksonen, K. Mäkelä, Department of Orthopaedics and Traumatology, Turku University Hospital, Turku, Finland; and University of Turku, Turku, Finland P. Pulkkinen, Department of Public Health, Helsinki University, Helsinki, Finland A. Eskelinen, Department of Orthopaedics and Traumatology, Coxa Hospital for Joint Replacement, Tampere, Finland A.-P. Puhto, Department of Orthopaedics and Traumatology, Oulu University Hospital, Oulu, Finland J. Kettunen, Department of Orthopaedics and Traumatology, Kuopio University Hospital, Kuopio, Finland J. Leskinen, Department of Orthopaedics and Traumatology, Helsinki University Central Hospital, Helsinki, Finland M. Manninen, Orton Hospital, Helsinki, Finland.
Clin Orthop Relat Res. 2018 Jun;476(6):1223-1230. doi: 10.1007/s11999.0000000000000159.
Large-diameter head metal-on-metal (MoM) THA has largely been abandoned as a result of higher than anticipated revision rates. However, the majority of these implants are still in situ. Although earlier reports from the Finnish Arthroplasty Register noted similar short-term survivorship between large-diameter head MoM THA and conventional cemented THA, longer term survivorship of this population is unclear. Although reported revision rates for this implant group have been high, the majority of these implants have not been revised and followup is important to improve long-term management.
QUESTIONS/PURPOSES: The purposes of this study were (1) to compare the 10-year competing risk survivorship of large-diameter head MoM THA with the survivorship of conventional THA in the Finnish Arthroplasty Register; (2) to report the large-diameter head MoM THA survival at the manufacturer/brand level; and (3) to identify the most common reasons for revision of large-diameter head MoM THA in the Finnish Arthroplasty Register.
The six most commonly used large-diameter head (≥ 38 mm) MoM THA devices in Finland between years 2004 and 2013 were selected (n = 10,959 implants). The completeness of the Finnish Registry is > 95% in primary THA and patients are censored from the date of death or at the point of emigration; followup continued until the end of 2015. The conventional THA control group consisted of the two most frequently used devices (Vision/Bimetric and ABG II/ABG II) with metal-on-polyethylene or ceramic-on-ceramic bearing surfaces implanted between 2002 and 2013 (n = 5177). The study group was formed by selecting all pairs of large-diameter head MoM and reference THA protheses within the same age group ( < 49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years), sex, diagnosis (osteoarthritis, other), and hospital yearly operation count (< 100 operations yearly, ≥ 100 operations yearly); 5166 matched pairs were identified. Revision for any reason was considered as the failure endpoint of followup. Implant survival (the proportion not revised) was calculated from corresponding cumulative incidence function adjusted for patient death as a competing event for revision. Large-diameter head MoM implant group revision hazard ratios with 95% confidence intervals were estimated with age group, sex, diagnosis, and hospital yearly operation count as confounding factors in a Cox regression model.
Ten-year survivorship free from all-cause revision was lower for THAs that used a large-diameter femoral head than it was for the control group of conventional THA (83% [95% confidence interval {CI}, 82%-84%] versus 92% [95% CI, 91%-93%]). At the implant level, every large-diameter head MoM THA had a higher risk for revision compared with the conventional THA control group from the fourth postoperative year onward. The highest survival of MoM THA was 88% (95% CI, 86%-90%) for the ReCap/Bimetric and the lowest survival was 46% (95% CI, 41%-51%) for the recalled ASR with either the Summit® or Corail® stem. The most common revision reason in the MoM THA group was adverse reaction to metal debris, whereas dislocation was predominant in the conventional THA control group.
The revision rate for all large-diameter head MoM THAs in this timeframe in the Finnish Arthroplasty Register is unacceptably high and in our view supports the decision to abandon their use. In agreement with the directives of other national organizations, we recommend regular followup of all patients with large-diameter head MoM THA. Based on our results, strict guidelines for followup should be maintained over the lifetime of the implant to assess patient symptoms and recommend revision when indicated.
Level III, therapeutic study.
由于较高的翻修率,大直径头金属对金属(MoM)THA 已基本被弃用。然而,这些植入物中的大多数仍在原位。尽管芬兰关节置换登记处的早期报告指出,大直径头 MoM THA 和传统骨水泥 THA 的短期生存率相似,但该人群的长期生存率尚不清楚。虽然报告的这种植入物组的翻修率很高,但大多数植入物尚未进行翻修,随访对于改善长期管理很重要。
问题/目的:本研究的目的是:(1)比较大直径头 MoM THA 在芬兰关节置换登记处与传统 THA 的 10 年竞争风险生存率;(2)报告制造商/品牌层面的大直径头 MoM THA 生存率;(3)确定芬兰关节置换登记处大直径头 MoM THA 翻修的最常见原因。
选择了芬兰 2004 年至 2013 年间最常用的六种大直径头(≥38mm)MoM THA 装置(n=10959 个植入物)。芬兰注册中心在初次 THA 中完整率>95%,患者在死亡或移民时截止;随访继续到 2015 年底。传统 THA 对照组由两种最常用的装置(Vision/Bimetric 和 ABG II/ABG II)组成,它们使用金属对聚乙烯或陶瓷对陶瓷轴承表面,植入时间为 2002 年至 2013 年(n=5177)。研究组由在同一年龄组(<49、50-54、55-59、60-64、65-69、70-74 和 75+ 岁)、性别、诊断(骨关节炎、其他)和医院每年手术量(<100 次手术/年,≥100 次手术/年)内选择的所有大直径头 MoM 和参考 THA 假体对组成;共确定了 5166 对匹配的假体。任何原因的翻修为随访的失败终点。通过相应的累积发病率函数计算植入物生存率(未修正的比例),调整患者死亡作为修正的竞争事件。在 Cox 回归模型中,使用年龄组、性别、诊断和医院每年手术量作为混杂因素,估计大直径头 MoM 植入物组的修正危险比及其 95%置信区间。
与对照组传统 THA(83%[95%置信区间,82%-84%])相比,使用大直径股骨头的 THA 10 年全因翻修生存率较低(92%[95%置信区间,91%-93%])。在植入物水平上,从术后第四年开始,每个大直径头 MoM THA 的翻修风险都高于对照组传统 THA。MoM THA 的最高生存率为 88%(95%置信区间,86%-90%),用于 ReCap/Bimetric,最低生存率为 46%(95%置信区间,41%-51%),用于召回的 ASR 与 Summit®或 Corail®柄。MoM THA 组最常见的翻修原因是金属碎屑的不良反应,而在对照组传统 THA 中,脱位是主要原因。
在芬兰关节置换登记处,这个时间框架内所有大直径头 MoM THA 的翻修率都高得令人无法接受,在我们看来,这支持了停止使用它们的决定。与其他国家组织的指示一致,我们建议对所有使用大直径头 MoM THA 的患者进行定期随访。根据我们的结果,应在植入物的整个生命周期内保持严格的随访指南,以评估患者的症状,并在需要时建议进行翻修。
三级,治疗性研究。